Cannara Biotech Company Spotlight
In this episode, David Flores sits down with Cannara CFO Nicholas Sosiak, to discuss the Company's future goals and to spotlight what differentiates Cannara from other companies in the cannabis space.
Similar Posts
Curing Alcoholism with Ketamine Therapy? | Interview with Psychedelic Scientist Dr. Ben Sessa -Awakn
In today’s episode of The Psychedelic Investor, James Hallifax interviews Dr. Ben Sessa of Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a psychedelic medicines company.
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Dr. Ben Sessa is the Chief Medical Officer of Awakn and a well-known scientist in the psychedelics field.
In this conversation, Awakn’s newest clinical trial is discussed. The phase 2 trial treated Alcohol Use Disorder using ketamine-assisted therapy, and the results were amazing. For example, by the end of the trial, 86% of participants remained abstinent from alcohol.
From this trial, it is clear that psychedelic therapy, or in this case ketamine therapy, can help with treating addiction. Perhaps the implications of the study go further.
Perhaps, psychedelics can treat mental health issues in general.
Perhaps, ketamine can be used to heal.
In the conversation, MDMA to treat addiction was also discussed.
Interestingly, Dr. Ben Sessa may be the only person in the world who has LEGALLY taken MDMA, psilocybin, LSD and Ketamine.
With mental health care in the spotlight, and we so obviously have a mental health crisis, psychedelic medicines are seeming more likely to be the answer.
From an investment perspective, psychedelic stocks are looking like they could be the next big thing. While there is no guarantee that Awakn will ultimately be a winner, their psychedelic research is definitely a boon for all psychedelic stocks.
#Psychedelics #Awakn #PsychedelicStocks
Can Next Generation Psychedelics Treat Mental Illness? | Mindset Pharma | DMT, 5-MEO-DMT
In today’s episode of the Psychedelic Spotlight Podcast, The Psychedelic Investor sits down with James Lanthier, CEO of Mindset Pharma (CSE: MSET, OTC: MSSTF).
Mindset Pharma is a psychedelic medicines company working on creating next-generation psychedelics to be used both in a therapy and microdosing setting.
Mindset has three variations of psilocybin, the active ingredient in Magic Mushrooms. Two of these are being used in therapy settings, and one will be used for microdosing. Finally, the company has one family of compounds inspired by DMT and 5-MEO-DMT.
Excitingly, Mindset is moving towards beginning clinical trials in 2022.
On the day that the interview was recorded, Mindset released some major news; they are teaming up with Otsuka Pharmaceuticals to bring two of their drug families to market. As part of this deal, Mindset will receive $5 million USD upfront, and then Otsuka will also pay for some development costs.
In the long term, this deal has great potential for Otsuka.
To learn more about Mindset pharma and its stock, listen to the full interview. In it we attempt to answer questions such as:
Can psychedelics treat mental illnesses such as depression?
Are next-generation psychedelics better than the originals?
What is happening in the brain when a person takes psychedelics?
Enjoy the episode!
You can find Mindset Pharma trading on the Canadian Securities Exchange under the symbol $MSET and on the American OTC market under the symbol $MSSTF.
*To learn more about Mindset Pharma visit their website: https://www.mindsetpharma.com/
#MindsetPharma #DMT #microdosing
My Neuroplastic Adventure with Victor Mifsud
In this episode, Dennis Walker speaks with Victor Mifsud about how a few MDMA experiences helped him have a temporary remission of his retinitis pigmentosa, a disease which has caused him to be legally blind.
What are the Benefits of MICRODOSING Psilocybin? | Interview with a Microdosing Expert
What are the benefits of Microdosing psilocybin? | Interview with a Microdosing Expert
In today’s episode, we sit down with microdosing expert Sena Maria of The Medicine of Being Human and MicrodosingForResilience.com.
In this interview, we learn about Sena’s microdosing business, which helps people begin microdosing psilocybin (note she does not provide any illegal substances, only coaches people on how to microdose) and the benefits that microdosing can bring.
For example, Sena gives us a fantastic Top 5 Benefits of Microdosing at some point in our chat.
Some of the questions that we covered were:
-What is microdosing and what are the benefits?
-How/ why did you start microdosing ?
-What is your microdosing regiment?
-What benefits have you personally seen from this?
-What do you wish people knew about psychedelics that they don’t currently?
-Can Microdosing magic mushrooms help with addiction?
-Can microdosing help treat depression or anxiety?
On top of discussing the how and why of microdosing psychedelics, Sena also discussed how these medicines have been known for generations in some aboriginal tribes, and how Western Medicine may still have a lot to learn.
Timestamps
00:00- Intro
1:32 – Sena Maria’s journey to microdosing: From Google to Psychedelics
4:15- Microdosing For Resilience
5:58- How to microdose psilocybin
8:20- Top 5 benefits of Microdosing
13:31- What is missed in the psychedelics conversation?
18:34- Sena’s Psychedelic Ceremony experiences
22:05 – How did you integrate what you learned in your psychedelic ceremony
#Microdosing #MicrodosingBenefits #Psychedelics
Functional Fungi and Microdosing for Optimal Wellbeing with Alli Schaper, Into The Multiverse
In this episode, Alli speaks on functional mushrooms for health: what they are, why they’re important, and what benefits they provide. She also delves into how functional mushrooms, when combined with psychoactive mushrooms such as psilocybin, impact the body.
Discussing Mindset Pharma’s 2022 Milestones and Future Plans with James Lanthier
In this conversation, David and James discuss the great deal of work that Mindset has done to set the stage for the launch of one or more drug candidates into first in-human clinical trials in 2023.